XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 6 Months Ended
Oct. 02, 2021
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
14. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company's chief operating decision maker.
The Company's reportable segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and restructuring related costs, deal amortization, gains and losses on dispositions and sale of assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation, transaction and integration costs and certain tax settlements and unusual or infrequent and material litigation-related charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months EndedSix Months Ended
(In thousands)October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net revenues
Plasma$82,004 $78,718 $153,807 $147,433 
Blood Center75,259 74,715 146,995 154,029 
Hospital75,902 51,022 153,509 96,593 
Net revenues by business unit233,165 204,455 454,311 398,055 
Service (1)
4,951 5,342 10,219 10,424 
Effect of exchange rates1,781 (311)3,895 (3,416)
Net revenues$239,897 $209,486 $468,425 $405,063 
(1) Reflects revenue for service, maintenance and parts
Three Months EndedSix Months Ended
(In thousands)October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Segment operating income
Plasma$42,213 $40,823 $77,559 $77,173 
Blood Center34,600 33,757 68,482 72,502 
Hospital31,229 21,459 62,826 39,242 
Segment operating income108,042 96,039 208,867 188,917 
  Corporate expenses (1)
(68,186)(56,741)(136,917)(121,803)
  Effect of exchange rates3,934 3,647 9,746 4,358 
  Integration and transaction costs(625)(1,773)(17,358)(3,063)
  Deal amortization(11,400)(8,136)(23,779)(16,399)
  Restructuring and restructuring related costs
(4,513)(4,440)(14,568)(8,440)
  Impairment of assets and PCS2 related charges(250)(576)(3,893)(3,082)
  MDR and IVDR costs(2)
(2,347)(736)(4,718)(1,489)
  Litigation-related charges(145)— (1,083)— 
  Gains on divestitures and sale of assets— 31,498 9,603 31,498 
Operating income$24,510 $58,782 $25,900 $70,497 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
(2) Refers to the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) costs.
Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
 Three Months EndedSix Months Ended
(In thousands)October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Plasma products and services$102,075 $97,710 $192,584 $186,423 
Blood Center products and services59,931 59,233 117,678 119,900 
Hospital products and services77,891 52,543 158,163 98,740 
Net revenues$239,897 $209,486 $468,425 $405,063 

Net revenues generated in the Company's principle operating regions on a reported basis are as follows:
Three Months EndedSix Months Ended
(In thousands)October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
United States$152,106 $123,984 $293,134 $234,993 
Japan18,812 19,645 36,033 36,476 
Europe41,180 38,648 84,515 81,667 
Asia26,771 26,168 52,723 48,552 
Other1,028 1,041 2,020 3,375 
Net revenues$239,897 $209,486 $468,425 $405,063